Wednesday, 01 Apr 2020

You are here

Aspirin after Hip or Knee Arthoplasty

JAMA Internal Medicine has reported that use of low dose aspirin for venous thromboembolism (VTE) prophylaxis after total hip and knee replacement is equal in efficacy to other anticoagulants.

A systematic review of 13 randomized clinical trials (6060 participants) examined the risk of VTE after total hip and knee replacement compared with other anticoagulants. They assessed VTE prevention as well as drug side effects.  

The risk of VTE after THR and TKR was 1.12 (95% CI, 0.78-1.62) for aspirin compared with other anticoagulants (including heparin, clexane, dabigatran, rivaroxaban, and warfarin).

ASA was also comparable in preventing deep vein thrombosis (DVT) (RR, 1.04; 95% CI, 0.72-1.51) or pulmonary embolism (PE) (RR, 1.01; 95% CI, 0.68-1.48).

Adverse events (major bleeding, wound hematoma, wound infection) were also not higher in those receiving aspirin compared to other anticoagulants.

The same results were seen when examining risks with THRs and TKRs separately.

While none of these studies were designed as non-inferiority studies, this analysis of efficacy and safety suggests that aspirin is comparable to other anticoagulants. Cost-effectiveness was not studied.

The use of aspirin would be considered an off-label use for VTE prevention in both the United States and the United Kingdom. However, there are some concerns that the newer and more expensive oral agents may have higher bleeding risks, including major hemorrhage and wound problems.5 Therefore, considerable debate remains about which agents should be preferred given that clinical effectiveness must be balanced against bleeding risk and cost.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

COVID Infection Run Down with Dr. Kevin Winthrop

Dr Kevin Winthrop answers COVID questions and advocates for "hit the pause button, lay low and exercise". We discuss the utility of baricitinib, losartan, COVID testing, Next Success and who to listen to.

Dr. Artie Kavanaugh - Don't Stop!

Drs. Cush and Kavanaugh discuss the downside of stopping hydroxychloroquine, DMARDs and biologics in lupus, RA and pregnancy.

Venom Peptide-Steroid Conjugate Effective in Collagen Induced Arthritis

Science Translational Medicine features a report from the Fred Hutchinson Cancer Research Center showing that a scopion venom peptide, coupled to steroid, can significantly reduce joint inflammation in a rat model of rheumatoid arthritis (RA).

ACR Releases Reproductive Health Guidelines for Rheumatic Diseases

Today, the American College of Rheumatology (ACR) published the 2020 Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. This is the first, evidence-based, clinical practice guideline related to the management of reproductive health issues for all patients with rheumatic diseases.

Adverse Effects of Low-Dose Methotrexate from the CIRT Trial

Low-dose methotrexate (LD-MTX) was studied in high risk cardiac patients in the cardiac intervention trial (CIRT), but was prematurely ended for not showing a change in cardiovascular event rates. Nonetheless this trial studied the safety and adverse event rates of LD-MTX and those results are reported in the current issue of Annals of Internal Medicine.